Icotinib
As of the edition of 20 October 2026, Icotinib is a small molecule: marketed; acts on EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Zhejiang Beta Pharma Inc.
- Registered trials
- 85, 4 stopped early
- Disease areas
- Cancer; Lungs and airways; Nervous system; Digestive system; Skin and connective tissue; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 0 | 1 | 0 |
| Phase 1 | 7 | 2 | 1 | 1 |
| Phase 2 | 51 | 11 | 3 | 2 |
| Phase 3 | 14 | 5 | 1 | 1 |
| Phase 4 | 9 | 2 | 0 | 0 |
| All trials | 85 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Betta Pharmaceuticals | Lead sponsor of trials | 2009 to now |